VENT-03
Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03, an Oral cGAS Inhibitor, in Lupus
Ventus Therapeutics; VENT-03; cGAS inhibitor; Phase 2 trial; lupus; cutaneous lupus erythematosus; autoimmune disease; interferon pathway; biomarkers; oral small molecule; clinical trial; immunology; cardiometabolic; inflammaging